Browse by author
Lookup NU author(s): Dr Alexei von Delwig, Professor John IsaacsORCiD, Dr Norman Balfour-McKie, Professor John Robinson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Objective. Type II collagen (CII) is a candidate autoantigen implicated in the pathogenesis of rheumatoid arthritis (RA). Posttranslational glycosylation of CII could alter intracellular antigen processing, leading to the development of autoimmune T cell responses. To address this possibility, we studied the intracellular processing of CII for presentation of the arthritogenic glycosylated epitope CII259-273 to CD4 T cells in macrophages from HLA-DR1-transgenic mice. Methods. HLA-DR1-transgenic mice were generated on a class II major histocompatibility complex-deficient background, and T cell hybridomas specific for the glycosylated and nonglycosylated epitope CII 259-273 were developed. Subcellular fractionation of macrophages was used to localize CII degradation to particular compartments and to identify the catalytic subtype of proteinases involved. Results. We showed that the glycosylated CII259-273 epitope required more extensive processing than did the nonglycosylated form of the same epitope. Dense fractions containing lysosomes were primarily engaged in the processing of CII for antigen presentation, since these compartments contained 1) enzyme activity that generated antigenic CII fragments bearing the arthritogenic glycosylated epitope, 2) the antigenic CII fragments themselves, 3) CII peptide-receptive HLA-DR1 molecules, and 4) peptide/HLA-DR1 complexes that could directly activate T cell hybridomas. Degradation of CII by dense fractions occurred optimally at pH 4.5 and was abrogated by inhibitors of serine and cysteine proteinases. Conclusion. Processing of the arthritogenic glycosylated CII259-273 epitope, which is implicated in the induction of autoimmune arthritis, is more stringently regulated than is processing of the nonglycosylated form of the same epitope. Mechanisms of intracellular processing of the glycosylated epitope may constitute novel therapeutic targets for the treatment of RA. © 2006, American College of Rheumatology.
Author(s): Balfour-McKie JN; Von Delwig A; Isaacs JD; Robinson JH; Altmann DM; Harding CV; Holmdahl R
Publication type: Article
Publication status: Published
Journal: Arthritis and Rheumatism
Year: 2006
Volume: 54
Issue: 2
Pages: 482-491
Print publication date: 01/02/2006
ISSN (print): 0004-3591
ISSN (electronic): 1529-0131
Publisher: John Wiley & Sons, Inc.
URL: http://dx.doi.org/10.1002/art.21565
DOI: 10.1002/art.21565
PubMed id: 16447222
Altmetrics provided by Altmetric
